SMMT publishes Phase III HARMONi analysis in Lancet Oncology
SMMT publishes primary analysis results from its global Phase III HARMONi study of ivonescimab plus chemotherapy in The Lancet Oncology.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.